Patients with severe COVID-19 who were given imatinib had lower mortality rates at 90-day follow-up, according to research published at the ATS 2022 international conference.
May 18, 2022
0
2
Black children with type 1 diabetes (T1D) experience disparities in health outcomes compared with other racial and ethnic groups with similar neighborhood opportunity profiles, according to a study published online May 5 ...
May 9, 2022
0
2
A team of researchers at the University of Pennsylvania has found that administration of a drug currently used to reduce cholesterol levels in the bloodstream can reduce the risk of developing proliferative diabetic retinopathy ...
Inhaled nitric oxide (iNO) is associated with improvement in the mean partial pressure of oxygen (PaO2)/fraction of inspired oxygen (FiO2) ratio (P/F ratio) among patients hospitalized with COVID-19 and mild-to-moderate acute ...
Apr 22, 2022
0
7
New research shows that a treatment for retinal vein occlusion yields long-lasting vision gains, with visual acuity remaining significantly above baseline at five years. However, many patients require ongoing treatment. Retinal ...
Apr 21, 2022
0
14
Indigenous people in Australia experience three times more vision loss than non-Indigenous people, creating a concerning gap for vision.
Apr 19, 2022
0
2
(HealthDay)—Faricimab is noninferior to aflibercept for the treatment of neovascular age-related macular degeneration (nAMD) and diabetic macular edema, according to two studies published online Jan. 24 in The Lancet.
Feb 2, 2022
0
2
Cerebral edema is a dangerous complication in many brain-related conditions such as strokes. Researchers at the Institute of Neurobiology at Heinrich Heine University Düsseldorf (HHU) have developed a new measurement method ...
Jan 31, 2022
0
10
(HealthDay)—Children with type 2 diabetes (T2D) have an increased risk for developing diabetic retinopathy compared with those with type 1 diabetes (T1D), according to a study published online Dec. 2 in JAMA Ophthalmology.
Dec 3, 2021
0
4
(HealthDay)—The first biosimilar to Lucentis (ranibizumab injection) has been approved for the treatment of neovascular (wet) age-related macular degeneration and other eye diseases and conditions, the U.S. Food and Drug ...
Sep 24, 2021
0
11
